Dizal (Jiangsu) Pharmaceutical Co., Ltd.
π¨π³China
- Country
- π¨π³China
- Ownership
- Public
- Established
- 2017-10-27
- Employees
- 581
- Market Cap
- -
- Website
- http://www.dizalpharma.com
DZD9008 PK Study in Hepatic Impairment Subjects
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT06084104
- Locations
- πΊπΈ
Orlando Clinical Research Center, Orlando, Florida, United States
πΊπΈAmerican Research Corporation, San Antonio, Texas, United States
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT05176873
- Locations
- πΊπΈ
Frontage Clinical Service 200 Meadowlands Parkway, Secaucus, New Jersey, United States
Β© Copyright 2025. All Rights Reserved by MedPath